Loading…
Ken GriffinReduced
Citadel Advisors · Q2 2026
$9.31M
255.81K shares · 0.0% of portfolio
Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc. (HRMY) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in Plymouth Meeting, United States and has 293 employees. The company is worth $2.1B and trades at 12.3x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $868.45M in fiscal 2025, up 21.5% from the year before. Net income was $158.69M. The share price is 17.2% below its 52-week high of $43.49. 6 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Renaissance Technologies, at $43.52M. In that quarter, 3 of them opened or added to the position and 2 reduced it. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▲ +11.3% over 5Y.
today you would have $915.12▼ -8.5%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 6 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Year-end price | $37.42 | $34.41 | $32.30 | $55.10 | $42.64 | $36.15 | |
| P/E | 15.2x | 13.8x | 13.7x | 15.2x | 18.6x | 73.5x | — |
| P/S | 5.3x | 2.5x | 2.8x | 3.2x | 7.5x | 8.2x | 12.9x |
| P/B | 6.0x | 2.5x | 3.0x |
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
Earnings growing 25.0% a year plus a 0.0% dividend yield. Growth capped at 25%.
Median P/E of 24.3 among peers in the sector.
Median P/E of 15.2 across this company’s own years on record.
Cash flow growing 15.0% a year for 10 years, discounted at 10%, then 2.5% forever.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| INSPInspire Medical Systems, Inc. | $72.66 | 16.0x | 2.5x | 0.00% | 17.96% | $2.1B |
| VERAVera Therapeutics, Inc. | $29.05 | — | 5.1x | 0.00% | -91.75% | $2.09B |
| NEONeogenomics Inc | $16.39 | — | 2.7x | 0.00% | -6.33% | $2.11B |
| SGRYSurgery Partners, Inc. | $15.90 |
| 3.9x |
| 8.2x |
| 13.5x |
| 21.2x |
| EPS | $2.71 | $2.51 | $2.13 | $2.97 | $0.58 | -$2.48 |
| Profit margin | 19.31% | 18.27% | 20.36% | 22.14% | 41.44% | 11.33% | -23.13% |
| ROE | 20.31% | 18.24% | 22.07% | 27.59% | 45.05% | 18.55% | -38.02% |
Median of the years shown; P/E years above 200x are left out.
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
5 methods answered, across 2 families.
Room for errors in the reported numbers.
+276.5% from the average.
Models, not forecasts, and not investment advice. How each formula works →
| — |
| 1.2x |
| 0.00% |
| 2.32% |
| $2.08B |
| LKFTLakefront Biotherapeutics NV | $31.40 | 2.9x | 11.2x | 0.00% | 20.12% | $2.06B |
| AXGNAxogen, Inc. | $36.68 | — | 7.7x | 0.00% | -18.21% | $2.15B |
